The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, 110801, China
Location status: Recruiting
NCT Number: NCT07286656
To evaluate the safety and tolerability of single ascending subcutaneous doses of GenSci098 in patients with Graves' Disease
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 1
Shenyang, Liaoning, 110801, China
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 141 days
This outcome measure assesses the incidence and severity of adverse events (AEs) experienced by participants during the study. AEs will be monitored through physical examinations, vital signs, laboratory tests, and 12-lead electrocardiograms (ECGs). The assessment period spans from the first dose of the study intervention to 141 days post-dosing.
Contact information is provided by the study sponsor or research team.
Changchun GeneScience Pharmaceutical Co., Ltd.
Industry
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Dose of GenSci098 in Patients With Graves' Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06569758
Autoimmune Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07016802
Adult Growth Hormone Deficiency, Bone Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT06243354
Efficacy, Safety
Fuzhou, Fujian, China
View Trial DetailsNCT06639256
Efficacy, Safety
Jinan, China
View Trial Details